A team led by Paul Hergenrother at the University of Illinois, Urbana Champaign (UIUC) has developed a novel antibiotic named lolamicin that was specific for gram-negative bacteria but did not harm the gut microbiome composition in mouse models.

Netherton syndrome (NS) is a rare genetic disease caused by loss of functional lympho-epithelial Kazal-type-related inhibitor (LEKTI, SPINK5). It was hypothesized that small-molecule inhibitors of KLK5 could replace deficient LEKTI in NS.

C-C chemokine receptor type 6 (CCR6) regulates the migration and recruitment of T cells in inflammatory and immunological processes and, as part of the CCR6-CCL20 axis together with its exclusive binding molecule CCL20, plays a critical role in maintaining immunological homeostasis during inflammation and infection.

A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting STAT3 inhibitors.

Annually in the U.S., about 40,000 people with corneal endothelial cell dystrophy receive a corneal transplant. The ligand of melanocortin MC1 receptor (MC1R) has been shown to protect the corneal endothelial cells from stress and injury in several models.

Researchers from the Icahn School of Medicine at Mount Sinai and affiliated organizations presented the discovery and preclinical characterization of MS-8535, a novel spindlin-1 (SPIN1) inhibitor being developed as chemical tool anticancer agent.

Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.

Amicetin-inspired inhibitors of the P-site (AIIPS), also known as CZ-02s, are a series of molecules that target and inhibit a unique site of the bacterial ribosome.

Debiopharm International SA has developed and presented a Fabl inhibitor, gofabicin, for the treatment of antibiotic-resistant Neisseria gonorrhoeae.